Protagonist Therapeutics (PTGX) Stock
Biotech company developing peptide treatments for gut conditions. Here's the price, business snapshot, and what's worth knowing about Protagonist Therapeutics in August 2026.
Protagonist Therapeutics (PTGX) is a clinical-stage biotechnology company developing peptide-based therapies, principally for gastrointestinal and immune-mediated conditions. With a market capitalisation around $4.67bn, the company’s value is driven by progress across its development pipeline, clinical trial data and any regulatory or partnership milestones. Investors should note Protagonist is not a commercial-stage pharmaceutical group: its prospects depend on successful trials, regulatory approvals and potential collaborations or licensing deals. That creates upside if candidates advance, but also material downside if trials fail or funding needs intensify. Typical risks include clinical and regulatory setbacks, high research and development spending, and share price volatility common to clinical-stage biotechs. This summary is for educational purposes only; it is not financial advice. Consider your risk tolerance and investment horizon and consult a qualified adviser before making decisions.
About This Stock
PROTAGONIST THERAPEUTICS INC
PTGX
Current Price
$150.68
Potential 12 Month Profit
-16.73%
Sector
Healthcare
Industry
Biotechnology & Medical Research
Ticker
PTGX
Market Cap
$9.74B
Potential 12 Month Profit
-16.73%
Sector
Healthcare
Industry
Biotechnology & Medical Research
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend purchasing Protagonist Therapeutics' stock, expecting it to increase in value.
Financial Health
Protagonist Therapeutics is generating solid cash flow and revenue, indicating healthy financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Milestones
Clinical data and regulatory updates can rapidly change prospects, offering potential upside — though results are uncertain and setbacks are possible.
Clinical Reach
Programmes target gastrointestinal and immune conditions with substantial patient need, but commercial success depends on approvals and market access.
Innovation and Risk
Peptide-based approaches may offer novel therapies, yet they come with high R&D costs and binary trial outcomes; consider this if you seek higher-risk exposure.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.